INCB 18424-258: An Open Label Assessment of Safety And Efficacy Of Ruxolitinib (INCB018424) In Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-Myelofibrosis and Post Polycythemia Vera-Myelofibrosis Who Have Platelet Counts of 50 x 10(9)/L To 100 x 10(9)/ L Keywords: myelofibrosis

A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily with Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients with Relapsing-remitting Multiple Sclerosis

A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Add-on, Parellel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients with Parkinson's Disease Phase IV (Protocol TVP-1012/PM106)

A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) (SOLID-TIMI 52) Keywords: Cardiovascular Disease, Acute Coronary Syndrome, ACS

A Double-blind, Randomized, Placebo-controlled Phase III Study to Assess the Efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-Positive Non-Small Cell Lung Cancer (MAGRIT: MAGE-A3 as Adjuvant Non-Small Cell LunG CancerR ImmunoTherapy) Keywords: Lung Cancer, non-small cell